Frontiers in oncology · 2026
Prognostic heterogeneity in ASXL1-mutated AML and refinement by an immunophenotype-based score.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Yaming, Zhang Min, Huang Yali, Wan Junzhao, Liu Ping, Wang Ping, Zhou Zhen, Hu Fangya, Wang Jianta, Ma Dan, Kang Qian
Аннотация
INTRODUCTION: ASXL1 is a frequently mutated gene in acute myeloid leukemia (AML) and is clinically recognized as an adverse prognostic marker, yet its clinical impact remains markedly heterogeneous.
METHODS: Utilizing the BeatAML cohort, we integrated genomic, transcriptomic, immunophenotypic, and drug-sensitivity data to delineate this variability.
RESULTS: Although ASXL1 mutations remained an independent adverse factor in multivariable analyses, survival outcomes did not differ significantly between ASXL1-mutated patients and those lacking other high-risk lesions after excluding co-occurring adverse mutations, suggesting that ASXL1 status alone does not uniformly dictate prognosis. By stratifying ASXL1-mutated patients based on treatment response, we identified two biologically distinct subsets-complete remission (CR) versus relapsed/refractory (R/R)-characterized by divergent clinical outcomes. Comparative analyses revealed distinct transcriptional profiles, including upregulated MAP3K15 expression in ASXL1-mutated cases, alongside consistent immunophenotypic downregulation of CD11b, CD123, and HLA-DR in R/R patients. Leveraging these routinely measured markers, we developed a three-parameter ImmuScore that robustly stratified prognosis in both the BeatAML cohort and an independent clinical validation set. Importantly, the ImmuScore captured functional drug-response patterns: patients with low scores displayed significantly higher Z-scores-indicating reduced sensitivity across multiple chemotherapeutic and targeted agents.
DISCUSSION: These findings link immunophenotypic signatures to therapeutic vulnerability, providing a mechanistic explanation for treatment failure in a subset of ASXL1-mutated AML. To address potential small-sample bias, Firth penalized regression was applied. Collectively, this study demonstrates that ASXL1-mutated AML is not a monolithic high-risk entity. The ImmuScore provides a biologically informed and clinically feasible tool to identify truly high-risk ASXL1-mutated patients, potentially guiding personalized therapeutic strategies.
METHODS: Utilizing the BeatAML cohort, we integrated genomic, transcriptomic, immunophenotypic, and drug-sensitivity data to delineate this variability.
RESULTS: Although ASXL1 mutations remained an independent adverse factor in multivariable analyses, survival outcomes did not differ significantly between ASXL1-mutated patients and those lacking other high-risk lesions after excluding co-occurring adverse mutations, suggesting that ASXL1 status alone does not uniformly dictate prognosis. By stratifying ASXL1-mutated patients based on treatment response, we identified two biologically distinct subsets-complete remission (CR) versus relapsed/refractory (R/R)-characterized by divergent clinical outcomes. Comparative analyses revealed distinct transcriptional profiles, including upregulated MAP3K15 expression in ASXL1-mutated cases, alongside consistent immunophenotypic downregulation of CD11b, CD123, and HLA-DR in R/R patients. Leveraging these routinely measured markers, we developed a three-parameter ImmuScore that robustly stratified prognosis in both the BeatAML cohort and an independent clinical validation set. Importantly, the ImmuScore captured functional drug-response patterns: patients with low scores displayed significantly higher Z-scores-indicating reduced sensitivity across multiple chemotherapeutic and targeted agents.
DISCUSSION: These findings link immunophenotypic signatures to therapeutic vulnerability, providing a mechanistic explanation for treatment failure in a subset of ASXL1-mutated AML. To address potential small-sample bias, Firth penalized regression was applied. Collectively, this study demonstrates that ASXL1-mutated AML is not a monolithic high-risk entity. The ImmuScore provides a biologically informed and clinically feasible tool to identify truly high-risk ASXL1-mutated patients, potentially guiding personalized therapeutic strategies.